- ISIN
- US8162121045
- CUSIP
- 816212104
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jun 22, 2016
Highlights
- Market Cap
- $267.21M
- Enterprise Value
- $164.61M
- EPS (TTM)
- -$5.77
- Total Revenue (TTM)
- $1.78M
- Gross Profit (TTM)
- -$11.10M
- EBITDA (TTM)
- -$40.76M
- Year Range
- $5.60 - $15.57
- Target Price
- $16.00
- ROA (TTM)
- -52.63%
- ROE (TTM)
- 102.47%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
RNAC Performance Chart
Cartesian Therapeutics Inc. (RNAC) is up 38.0% since the beginning of the year. At $10 per share, RNAC is trading 36.1% below its 52-week high of $16. Investors who bought $1,000 worth of RNAC shares 5 years ago would now be looking at an investment worth $73.
Loading charts...
Returns By Period
Cartesian Therapeutics Inc. (RNAC) has returned 38.00% so far this year and 1.95% over the past 12 months. Over the last ten years, RNAC has returned -31.22% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
Cartesian Therapeutics Inc.
- 1D
- 3.32%
- 1M
- 47.41%
- YTD
- 38.00%
- 6M
- 48.07%
- 1Y
- 1.95%
- 3Y*
- -34.50%
- 5Y*
- -40.82%
- 10Y*
- -31.22%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
RNAC Monthly Returns History
Based on dividend-adjusted daily data since Jun 22, 2016, RNAC's average daily return is +0.02%, while the average monthly return is -0.29%.
Historically, 48% of months were positive and 52% were negative. The best month was May 2024 with a return of +57.3%, while the worst month was Oct 2018 at -67.0%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 6 months.
On a daily basis, RNAC closed higher 47% of trading days. The best single day was Dec 19, 2019 with a return of +45.2%, while the worst single day was Nov 7, 2017 at -54.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -5.27% | 11.13% | -18.97% | 1.14% | 21.22% | 31.96% | 38.00% | ||||||
| 2025 | 7.82% | -2.43% | -30.04% | -8.95% | -20.33% | 8.68% | 23.29% | -21.55% | 1.69% | -20.06% | -8.32% | -3.74% | -59.74% |
| 2024 | 4.44% | 1.60% | -11.14% | 13.18% | 57.32% | -22.21% | -39.65% | -14.36% | 15.47% | 22.83% | -4.90% | -4.89% | -13.40% |
| 2023 | 56.64% | -7.91% | -14.72% | -14.39% | -0.84% | -5.08% | -2.68% | 12.84% | -13.82% | 17.92% | 8.00% | -48.93% | -38.99% |
| 2022 | -23.31% | -26.00% | -33.51% | -37.70% | 15.12% | 48.49% | 21.37% | 18.24% | -12.77% | -3.66% | -17.09% | -13.74% | -65.34% |
| 2021 | 32.01% | 5.50% | 7.23% | -33.70% | 44.67% | -3.69% | -17.22% | 25.43% | -4.15% | -13.70% | -16.43% | 8.67% | 7.59% |
Benchmark Metrics
Cartesian Therapeutics Inc. has an annualized alpha of -13.86%, beta of 1.32, and R2 of 0.07 versus S&P 500 Index. Calculated based on daily prices since June 22, 2016.
- This stock participated in 118.90% of S&P 500 Index downside but only -47.98% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.07 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -13.86%
- Beta
- 1.32
- R²
- 0.07
- Upside Capture
- -47.98%
- Downside Capture
- 118.90%
Return for Risk
Risk / Return Rank
RNAC ranks 45 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Cartesian Therapeutics Inc. (RNAC) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| RNAC | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.01 | ||
| Sortino ratioReturn per unit of downside risk | -2.01 | ||
| Omega ratioGain probability vs. loss probability | 1.08 | 1.37 | -0.29 |
| Calmar ratioReturn relative to maximum drawdown | 0.03 | 2.78 | -2.75 |
| Martin ratioReturn relative to average drawdown | 0.05 | 12.44 | -12.39 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Cartesian Therapeutics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Cartesian Therapeutics Inc. was 99.26%, occurring on Jun 5, 2026. The portfolio has not yet recovered.
The current Cartesian Therapeutics Inc. drawdown is 98.74%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -99.26%Jun 2026 | 9y 6mo | — | 9y 6moNov 2016 - now |
2016 bear market2016 | -29.00%Aug 2016 | 1mo 19d | 1mo 14d | 3mo 3dJun 2016 - Sep 2016 |
2016 correction2016 | -16.26%Oct 2016 | 9d | 12d | 21dSep 2016 - Oct 2016 |
2016 pullback2016 | -7.33%Nov 2016 | 1d | 7d | 8dNov 2016 - Nov 2016 |
2016 pullback2016 | -5.47%Oct 2016 | 4d | 7d | 11dOct 2016 - Oct 2016 |
Drawdown Indicators
| RNAC | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.26% | -56.78% | -42.48% |
Max Drawdown (1Y)Largest decline over 1 year | -57.59% | -9.10% | -48.49% |
Max Drawdown (3Y)Largest decline over 3 years | -85.58% | -18.90% | -66.68% |
Max Drawdown (5Y)Largest decline over 5 years | -95.81% | -25.43% | -70.38% |
Max Drawdown (10Y)Largest decline over 10 years | -99.26% | -33.92% | -65.34% |
Current DrawdownCurrent decline from peak | -98.74% | -1.80% | -96.94% |
Average DrawdownAverage peak-to-trough decline | -80.65% | -10.71% | -69.94% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 40.59% | 2.03% | +38.56% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Cartesian Therapeutics Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Cartesian Therapeutics Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for RNAC relative to other companies in the Biotechnology industry. Currently, RNAC has a P/S ratio of 147.5. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with RNAC
Add Cartesian Therapeutics Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with RNAC